Universe Pharmaceuticals Inc
3 hedge funds and large institutions have $24K invested in Universe Pharmaceuticals Inc in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 2 closing their positions.
1.13% less ownership
Funds ownership: 1.33% → 0.2% (-1.1%)
25% less funds holding
Funds holding: 4 → 3 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
87% less capital invested
Capital invested by funds: $181K → $24K (-$157K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$6.49K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
-$150K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$10K |
UPC Hedge Fund Activity: Q3 2022 in Review
3 of the 5,829 institutional investors tracked by Wall St. Rank reported a position in Universe Pharmaceuticals Inc (UPC) for Q3 2022, worth a combined $24K — down 87% from $181K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of UPC and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest buyer was UBS Group, opening a new position worth an estimated $6.49K. The largest seller was Pura Vida Investments, exiting entirely with an estimated $150K sold.
- 3 institutional investors held Universe Pharmaceuticals Inc (UPC) as of Q3 2022, down from 4 in Q2 2022.
- Funds reported $24K of Universe Pharmaceuticals Inc stock for Q3 2022, down 87% quarter-over-quarter.
- 1 fund opened new Universe Pharmaceuticals Inc positions in Q3 2022 and 2 closed out, a net change of -1 holder.
- The largest Universe Pharmaceuticals Inc buyer in Q3 2022 was UBS Group, an estimated $6.49K added.
- The largest Universe Pharmaceuticals Inc seller in Q3 2022 was Pura Vida Investments, an estimated $150K sold.
Based on aggregated 13F filings for Q3 2022.